GlobalData

These therapies are expected to eliminate the need for further treatments and reduce the cost of disease management

GlobalData expects Ofev and Actemra/RoActemra to reach peak global sales of $508.8 million in 2025 and $163.2 million in 2024,…

The highlights of the latest reforms are the drug patent linkage system, introduction of patent term extension for drugs and the…

Slow enrollment was the top reason, followed by enrollment suspension and lastly delayed initiation

The upward trend for vaccine COVID-19 clinical trials is expected to continue while there will be a decrease in therapeutic…

Deal value decreased by 16.9 per cent in May 2021, compared to April 2021

The US will have the highest number of diagnosed prevalent cases of systemic sclerosis in the 7MM at 114,000

The next decade may see the introduction of personalised therapy options in locally advanced HNSCC settings along with…

There are currently 315 pain therapeutics in development globally

Viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the…